Have the challenges of creating an effective oral insulin finally been overcome?

Cardiovascular events decline for patients using which antidiabetic medication?

Can improving diabetes care be as simple as ensuring patients receive regular testing?

Data from the REWIND trial suggest that dulaglutide has cardioprotective properties. 

The combination of an SGLT2i plus a GLP-1 RA results in surprising effects on endogenous glucose production and HBA1c. 

Care of the elderly can be very challenging. Can adding yet another medication actually help?   

Is the risk as substantial as was initially reported?

The case for expanding screening for pancreatic cancer in those with new onset of diabetes and weight loss. 

Are SGLT-2 inhibitors responsible for urosepsis or Fournier's gangrene? 

In type 2 diabetes patients, treating diastolic function and myocardial perfusion reserve could improve aerobic exercise capacity and prevent heart failure.